Evidence map›Paper›PMID 32268022›Full record

ArticleThe New England journal of medicine2020

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.

Yan Zhang, Meng Xiao, Shulan Zhang, Peng Xia, Wei Cao, Wei Jiang, Huan Chen, Xin Ding, Hua Zhao, Hongmin Zhang and 25 more

4 registry-linked trialsAbstract readCase ReportsLetter
In one paragraph

Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 1,334 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,334citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04530578 phase4unknown statusnot on this map

Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)

TypeinterventionalSponsorClinica San Camilo, ArgentinaRan2020 to 2021Enrolled200ConditionsCovid19, PneumoniaArmsHeparin sodium, Enoxaparin
NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
NCT04602507 phase2terminatednot on this map

Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial

TypeinterventionalSponsorCES UniversityRan2020 to 2021Enrolled75ConditionsCovid19, Severe Acute Respiratory SyndromeArmsIvermectin, Placebo
NCT04869579 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients

TypeinterventionalSponsorCHRISTUS HealthRan2021 to 2021Enrolled100ConditionsCovid19ArmsSelenium (as Selenious Acid), Placebo
3 · Its place in the literature

Who cites it

1,334 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Effect of vitamin DClinics (Sao Paulo, Brazil) · 2024
    Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Review

1,274 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Yan ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Meng XiaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Shulan ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Peng XiaPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Wei CaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Wei JiangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Huan ChenPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Xin DingPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Hua ZhaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Hongmin ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Chunyao WangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Jing ZhaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Xuefeng SunPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Ran TianPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Wei WuPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Dong WuPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Jie MaPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Yu ChenPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Dong ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Jing XiePeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Xiaowei YanPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Xiang ZhouPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Zhengyin LiuPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Jinglan WangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Bin DuPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Yan QinPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Peng GaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Xuzhen QinPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Yingchun XuPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Wen ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Taisheng LiPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Fengchun ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Yongqiang ZhaoPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Yongzhe LiPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.
Shuyang ZhangPeking Union Medical College Hospital, Beijing, China yongzhelipumch@126.com shuyangzhang103@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntibodies, AnticardiolipinAntibodies, Anti-IdiotypicAntibodies, AntiphospholipidBlood Coagulation DisordersCoronavirus InfectionsCOVID-19HumansImmunoglobulin AImmunoglobulin GMalePandemicsPneumonia, ViralAntibodies, AnticardiolipinAntibodies, Anti-IdiotypicAntibodies, AntiphospholipidImmunoglobulin AImmunoglobulin G

Identifiers

PMID32268022
PMCPMC7161262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.